Last monthAtriCureAnnouncing itsAtriClip SeriesThe global sales volume of the left atrial appendage closure device has exceeded700,000 sets.
AtriClip SeriesThe left atrial appendage closure device is currently the most successful left atrial appendage closure device and the most widely implanted left atrial appendage closure device in the world, setting a benchmark for innovation in the field of left atrial appendage closure.AtriCureSince the conception in 2003 of closing the left atrial appendage through surgical means, AtriClipAlready more than 20 years in development. Currently supported by over 90 published research studies, proving the AtriClip Left Atrial Appendage Exclusion System is safe and effective.Currently, the left atrial appendage occluder hasUpgraded toClass IA ExtrapolationRecommended. According to the latest atrial fibrillation diagnosis and treatment guidelines released by the American College of Cardiology (ACC), the American Heart Association (AHA), the American College of Chest Physicians (ACCP), and the Heart Rhythm Society (HRS), left atrial appendage management has been upgraded to the highest level of recommendation.Since AtriCure has demonstrated the safety and efficacy of its left atrial appendage occluder through clinical evidence, and it is recommended by clinical guidelines, many innovative companies in China have started to follow suit. Among them, the most well-known medical device company is Medtronic. In 2023, Medtronic emerged from a renowned incubator.SyntheonAcquisition in HandLeft Atrial AppendageCloser---Penditure, to strengthen itsHeartCardiac Surgery BusinessMedtronic's left atrial appendage occluder, Penditure, has now received FDA and CE approval for market release, making it the largest international competitor to AtriClip’s series of left atrial appendage occluders.
The AtriClip Left Atrial Appendage Exclusion System is implanted epicardially during cardiac surgery at the base of the left atrial appendage, achieving permanent isolation between the left atrial appendage and the left atrium. This isolation blocks blood flow and electrical conduction between the left atrium and the left atrial appendage, ultimately resulting in electrical isolation of the left atrial appendage from the rest of the heart.AtriClip Product Features- The implant does not enter the bloodstream.
- Achieving Electrical Isolation of the Left Atrial Appendage Through Ischemic Injury
- Promote the atrophy and absorption of the left atrial appendage
- Continuous Dynamic Closure Pressure
Continuous clamping force ensures that the left atrial appendage remains isolated during tissue ischemic changes.Achieve optimal tissue apposition along the long axis of the left atrial appendage opening, minimizing tissue folding to the greatest extent.- Tissue Compression / Atraumatic Design
Non-cutting, non-piercing, and non-traumatic compression technology reduces the risk of tissue tearing and bleeding.AtriCure, in order to provide better treatment for atrial fibrillation patients, has developed various designs over two decades based on different patient anatomies.AtriClip Series Left Atrial Appendage ClosureCombined device. However, the design can be adapted for open-chest surgery and minimally invasive surgery via thoracic/port access. Each product comes with a size selection guide to facilitate accurate matching of the left atrial appendage clamp model.
AtriCure
AtriCureA company that provides innovative treatment technologies for patients with atrial fibrillation worldwide.Global electrophysiologists, cardiothoracic surgeons, and thoracic surgeons use anti-vasectomy technology to treat AFIB and reduce AFIB-related complications, as well as to manage postoperative pain.
